Dr Chris Hayes

Prior to joining Pangea Bio in November 2021, Chris was Vice President and Global Head of Intellectual Property at Jazz Pharmaceuticals, with responsibility for the strategic protection of all of the companies products and pipeline candidates, having joined Jazz on the acquisition of GW Pharmaceuticals plc.

At GW Chris was Vice President of Intellectual Property, where he was responsible for developing and implementing an IP strategy to protect GW’s entire portfolio of cannabis based products. Chris has extensive experience in the IP and exclusivity frameworks available to protect plant derived medicines. Chris’s work in developing GW’s IP strategy and portfolio was pivotal in the acquisition of GW by Jazz for $7.2Bn.

Prior to working at GW, Chris was an IP Partner in an international law firm, based in London. Chris has worked as an in-house IP lawyer for H Lundbeck A/S. Chris is a qualified barrister, having been called to the Bar of England and Wales by the Honourable Society of Gray’s Inn. Before training as a barrister, Chris has worked for Bristol Myers Squibb in scientific and medical affairs roles and Merck, Sharp and Dohme as a researcher, as well as holding academic positions at the University of Oxford. Chris was the recipient of a Medical Research Council Research Fellowship and was a Junior Research Fellow at Merton College, Oxford.

Chris has published in leading scientific and legal journals and has a doctorate in developmental genetics from the University of Oxford.